Search results
Results from the WOW.Com Content Network
Orexigen Therapeutics, Inc. is a public American pharmaceutical company focused on development of treatments for obesity. [1] The company is based in La Jolla, California and was established by Eckard Weber in 2002. [1] As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX. [1]
ORIX was established April 17, 1964 as Orient Leasing Co., Ltd. The company's name was changed to ORIX Corporation in 1989. ORIX was originally a subsidiary of the trading house Nichimen (now Sojitz).
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
Orexigen Therapeutics (NAS: OREX) was left for dead earlier this year when its obesity drug was shot down by the FDA. But today it had a message for investors that could be interpreted as "hold on ...
While obesity-drug rivals Arena Pharmaceuticals (NAS: ARNA) and VIVUS (NAS: VVUS) get nearly all of the publicity, Orexigen plugs along like the little engine that What Orexigen Is Saying -- and ...
Orexigen Therapeutics (OREX) shares are soaring over 25% in premarket trading after it announced n exclusive partnership agreement potentially worth over $1 billion with Japan's Takeda ...
Naltrexone/bupropion, sold under the brand name Contrave among others, is a fixed-dose combination medication for the management of chronic obesity in adults in combination with a reduced-calorie diet and increased physical activity.
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Orexigen Therapeutics (NAS: OREX ...